- Home
- SST vs EPIX Comparison
SST vs EPIX Comparison
Compare SST & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- EPIX
- Stock Information
- Founded
- SST 2013
- EPIX 2009
- Country
- SST United States
- EPIX Canada
- Employees
- SST N/A
- EPIX N/A
- Industry
- SST Diversified Commercial Services
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- SST Consumer Discretionary
- EPIX Health Care
- Exchange
- SST Nasdaq
- EPIX Nasdaq
- Market Cap
- SST 23.3M
- EPIX 75.9M
- IPO Year
- SST N/A
- EPIX N/A
- Fundamental
- Price
- SST $4.98
- EPIX $1.73
- Analyst Decision
- SST Strong Buy
- EPIX Hold
- Analyst Count
- SST 1
- EPIX 3
- Target Price
- SST $500.00
- EPIX $2.00
- AVG Volume (30 Days)
- SST 312.6K
- EPIX 52.3K
- Earning Date
- SST 08-07-2025
- EPIX 08-04-2025
- Dividend Yield
- SST N/A
- EPIX N/A
- EPS Growth
- SST N/A
- EPIX N/A
- EPS
- SST N/A
- EPIX N/A
- Revenue
- SST $333,521,000.00
- EPIX N/A
- Revenue This Year
- SST N/A
- EPIX N/A
- Revenue Next Year
- SST $8.39
- EPIX N/A
- P/E Ratio
- SST N/A
- EPIX N/A
- Revenue Growth
- SST N/A
- EPIX N/A
- 52 Week Low
- SST $2.90
- EPIX $1.40
- 52 Week High
- SST $15.70
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- SST 47.70
- EPIX 52.82
- Support Level
- SST $5.11
- EPIX $1.60
- Resistance Level
- SST $15.00
- EPIX $1.73
- Average True Range (ATR)
- SST 2.05
- EPIX 0.04
- MACD
- SST -0.10
- EPIX 0.00
- Stochastic Oscillator
- SST 16.22
- EPIX 66.67
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.